Recent Updates
Recently added Catalysts
ALGN Positive Sentiment Score: 60/100

Align Technology Announces Second Quarter 2026 Financial Results

Key Takeaway: Align Technology reported its Q2 2026 financial results, showing total revenues of $1,056.2 million. This represents a 1.5% increase sequentially and a 4.3% increase year-over-year. Despite the positive revenue growth, the company noted that total revenues were adversely affected by unspecified factors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Total revenues increased by 4.3% year-over-year.
  • Sequential revenue growth of 1.5% indicates stability.
  • Align Technology continues to lead in digital orthodontics.

CONCERNS & RISKS

  • Total revenues were unfavorably impacted by certain factors.
  • Specific challenges affecting revenue growth were not detailed.

Full Press Release Details

THOUSAND OAKS, Calif.,July 28, 2026/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website,www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
AboutAmgenAmgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.
More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.
Amgen has beenconsistently recognizedfor innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
For more information, visitAmgen.comand follow Amgen onX,LinkedIn,Instagram,YouTube,Facebook,TikTokandThreads.
CONTACT: Amgen, Thousand OaksElissa Snook, 609-251-1407 (media)Casey Capparelli, 805-447-1746 (investors)
SOURCE Amgen

Frequently Asked Questions

What were Align Technology's Q2 2026 total revenues?

Align Technology's total revenues for Q2 2026 were $1,056.2 million.

How much did revenues increase year-over-year?

Revenues increased by 4.3% year-over-year in Q2 2026.

What was the sequential revenue growth for Q2 2026?

The sequential revenue growth for Q2 2026 was 1.5%.

What impact did certain factors have on revenues?

Total revenues were unfavorably impacted by unspecified factors.

Last updated: Jul 29, 2026